More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Method to Produce “Aged” iPS Cells

SK2013-033

SUMMARY OF INVENTION

Patient-specific induced pluripotent stem cells (iPSCs) are a powerful tool for modeling disease phenotypes in vitro, and they have been successfully used to study early-onset disorders. Their value in modeling late-onset neurodegenerative diseases such as Parkinson’s or Alzheimer’s, in contrast, has been limited to date.

One problem has been the embryonic nature of iPSc-derived midbrain dopamine neurons.  This prevents them from fully recapitulating the severe degenerative pathology of these diseases.

This invention facilitates more accurate modeling of late-onset neurodegenerative disorders through a novel method that manipulates the cellular “age” of iPSc-derived dopamine neurons in vitro. The technology starts by reprogramming cell cultures into a de-differentiated state, and then inducing “aging” through the reintroduction of age-related markers that can control and accelerate the timeline.

ADVANTAGES

  • As a research tool, this method permits enhanced ability to model late-onset neurodegenerative diseases
  • Potential to produce a scalable supply of “aged” iPSCs for use in high throughput screening and other applications
  • Developed by outstanding scientific team with proven experience in stem cell innovation

MARKET OPPORTUNITIES

In the U.S. alone, there are an estimated 5.3 million patients with Alzheimer’s and another 1 million with Parkinson’s disease; the prevalence of these conditions will only increase as the population ages.  With no adequate treatments to restore proper dopaminergic neuron function, this is a high-priority research field which could benefit from a method that readily and accurately produces “aged” iPSCs.

AREAS OF APPLICATION

Research tool for use in modeling neurodegenerative diseases

STAGE OF DEVELOPMENT

Proof-of-concept in vitro

PATENT INFORMATION

Applications pending in U.S., Europe, Canada, Australia, and Japan

LEAD INVESTIGATOR

Lorenz Studer, MD/PhD, Director, Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center

CONTACT INFORMATION

Imke Ehlers, PhD, CLP, Senior Licensing Manager
Tel: 646-888-1074
E-mail: ehlersi@mskcc.org

Stage of Development

In vitro